BioSpace News Archive

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced that its management will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 12:00 p.m. Eastern Time.

Lack of reproducibility is a critical problem in biomedical science, wasting both time and billions of dollars every year.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on July 6, 2021 to all shareholders of record as of June 15, 2021.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D. Chief Scientific Officer /COO, will participate in two upcoming investor conferences:

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that the management team from Fortress’ commercial dermatology partner company, Journey Medical Corporation, will be featured in a webinar hosted by Scott R. Henry,

Preclinical data demonstrate potential of off-the-shelf, NK-like gamma-delta T cells in developing cell therapies for the treatment of cancers ACE1831, an allogeneic cell therapy candidate targeting hematological cancers, demonstrates prolonged survival in vivo

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Maurice Zauderer, chief executive officer, will deliver a company presentation at the 2021 Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021.

-- 43 abstracts on six investigational and approved medicines across 12 cancer types to be presented at both meetings -- New results from the Phase 2 CAPTIVATE study of ibrutinib (IMBRUVICA®) + venetoclax (VENCLEXTA®/VENCLYXTO®) combination regimen for frontline chronic lymphocytic leukemia (CLL) to be presented at ASCO among other significant oncology data at both congresses

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), the leading physician-led, science-focused multi-state cannabis company, today announced that it will host a series of online virtual events for the institutional and retail investment communities on Tuesday, June 8, 2021 and Wednesday, June 9, 2021 .

Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis of trial when 50% of planned subjects reach 6 months in study